In vitro evidence reveals how hepatic steatosis alters drug metabolism in patients with metabolic-associated liver disease, suggesting further studies are needed.
Hepatic steatosis selectively alters the metabolism of carbamazepine and levetiracetam in vitro without enhancing short-term cellular toxicity. These findings raise concerns about possible modifications in drug exposure, efficacy and tolerability in patients with MASLD, and underscore the need for further in vivo and clinical studies.
No takes yet. Share an insight, caveat, or question.
Plissonneau et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: